Prostate Cancer - Results from #540

Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry. July 22, 2024

The 30th Annual Prostate Cancer Foundation Scientific Retreat Report. July 19, 2024

Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer. July 19, 2024

PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer. July 19, 2024

Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancer. July 19, 2024

Prostate-specific antigen screening for prostate cancer: Diagnostic performance, clinical thresholds, and strategies for refinement. July 19, 2024

Target Volume Optimization for Localized Prostate Cancer. July 19, 2024

PROTAC'ing the androgen receptor and other emerging therapeutics in prostate cancer. July 19, 2024

Effects of high-intensity interval training on cardiometabolic biomarkers in patients with prostate cancer undergoing active surveillance: a randomized controlled trial. July 19, 2024

An 18-gene signature of recurrence-associated endothelial cells predicts tumor progression and castration resistance in prostate cancer. July 19, 2024

A Systematic Review of Family History, Race/Ethnicity, and Genetic Risk on Prostate Cancer Detection and Outcomes: Considerations in PSA-based Screening. July 19, 2024

Transcriptomic Profiling of Primary Prostate Cancers and Nonlocalized Disease on Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography: A Multicenter Retrospective Study. July 18, 2024

Metabolic imaging across scales reveals distinct prostate cancer phenotypes. July 18, 2024

Prostate magnetic resonance imaging utilization and its relationship with advanced prostate cancer detection. July 18, 2024

Single-dose high-dose-rate brachytherapy versus two and three fractions for locally advanced prostate cancer. July 18, 2024

Predicting Treatment Effects from Surrogate Endpoints in Historical Trials in First-Line Metastatic Castration-Resistant Prostate Cancer. July 18, 2024

Bayer Announces Positive Topline Results for NUBEQA® (Darolutamide) from Phase III Trial in Men with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) July 17, 2024

The Current Landscape of Stereotactic Body Radiation Therapy for Metastatic Castration-Resistant Prostate Cancer - Beyond the Absract July 17, 2024

Helical Tomotherapy versus Three-Dimensional Conformal Radiotherapy in High Risk Prostate Cancer: A Phase III Randomized Controlled Trial. July 17, 2024

Stereotactic Body Radiotherapy for Oligoprogression in Castration-Resistant Prostate Cancer: Early Toxicity Analysis of the TRAP Trial. July 17, 2024

Page 28 of 1435